Figure 1.

JDP-2 potentiation of the partial agonist activity of RU486 is dependent on the NTD of PR. A, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) and phPR-B (1.5 ng) or phPR-A (15 ng) together with pCR3.1-JDP-2 (100 ng) or an empty vector. B, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) and DBD-hLBD (10 ng) or phPR-B (1.5 ng) together with pCR3.1-SRC-1 (200 ng) or pCR3.1-JDP-2 (137 ng). C, COS-1 cells were transfected with PRE₂-TATA-Luc (200 ng) and phPR-B (1.5 ng) together with pCR3.1-SRC-1 (150 ng) or pCR3.1-JDP-2 (100 ng). Cells were treated for 24 h with vehicle, 10 nm R5020, 10 nm RU486, or 100 nm ZK98299 as indicated in panels A–C. Fold luciferase induction was calculated as a ratio of relative luciferase activation of ligand-treated cells divided by the corresponding vehicle-treated samples. Fold enhancement was calculated by setting luciferase induction of each receptor construct in each treatment group to 1.0, and corresponding values in the presence of JDP-2 or SRC-1 were calculated as folds relative to 1.0. This is a single representation of triplicate experiments.